Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR QC and Cardea Bio CRISPR-BIND

CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, and is built on Cardea's biology-gated transistors and an automated, high-throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.

CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.